Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice

被引:180
作者
Cyrus, T
Sung, S
Zhao, L
Funk, CD
Tang, S
Praticò, D
机构
[1] Univ Penn, Ctr Expt Therapeut, Sch Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA
关键词
atherosclerosis; aspirin; inflammation; plaque;
D O I
10.1161/01.CIR.0000027816.54430.96
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Atherosclerosis is a complex vascular inflammatory disease. Low-dose aspirin is a mainstay in the prevention of vascular complications of atherosclerosis. We wished to determine the effect of low-dose aspirin on vascular inflammation, plaque composition, and atherogenesis in LDL receptor-deficient mice fed a high fat diet. Methods and Results-In LDL receptor-deficient mice fed a high fat diet compared with control mice, low-dose aspirin induced a significant decrease in circulating levels and vascular formation of soluble intercellular molecule-1, monocyte chemoattractant protein-1, tumor necrosis factor-alpha, interleukin-12p 40, without affecting lipid levels. This was associated with significant reduction of the nuclear factor kappaB activity in the aorta. Low-dose aspirin also significantly reduced the extent of atherosclerosis. Finally, aortic vascular lesions of the aspirin-treated animals showed 57% reduction (P < 0.05) in the amount of macrophage cells, 77% increase in smooth muscle cells (P < 0.05), and 23% increase in collagen (P < 0.05). Conclusions-Our results suggest that in murine atherosclerosis, low-dose aspirin suppresses vascular inflammation and increases the stability of atherosclerotic plaques, both of which, together with its antiplatelet activity, contribute to its antiatherogenic effect. We conclude that low-dose aspirin might be rationally evaluated in the progression and evolution of human atherosclerotic plaque.
引用
收藏
页码:1282 / 1287
页数:6
相关论文
共 28 条
[1]  
[Anonymous], 1988, LANCET, V2, P349
[2]   Aspirin [J].
Awtry, EH ;
Loscalzo, J .
CIRCULATION, 2000, 101 (10) :1206-1218
[3]   Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion [J].
Brand, K ;
Page, S ;
Rogler, G ;
Bartsch, A ;
Brandl, R ;
Knuechel, R ;
Page, M ;
Kaltschmidt, C ;
Baeuerle, PA ;
Neumeier, D .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (07) :1715-1722
[4]   The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice - Evidence that eicosanoids other than thromboxane contribute to atherosclerosis [J].
Cayatte, AJ ;
Du, Y ;
Oliver-Krasinski, J ;
Lavielle, G ;
Verbeuren, TJ ;
Cohen, RA .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (07) :1724-1728
[5]   Indications for early aspirin use in acute ischemic stroke - A combined analysis of 40 000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial [J].
Chen, ZM ;
Sandercock, P ;
Pan, HC ;
Counsell, C ;
Collins, R ;
Liu, LS ;
Xie, JX ;
Warlow, C ;
Peto, R .
STROKE, 2000, 31 (06) :1240-1249
[6]   Selective inhibition of interleukin-4 gene expression in human T cells by aspirin [J].
Cianferoni, A ;
Schroeder, JT ;
Kim, J ;
Schmidt, JW ;
Lichtenstein, LM ;
Georas, SN ;
Casolaro, V .
BLOOD, 2001, 97 (06) :1742-1749
[7]   SUPPRESSION OF THROMBOXANE-A2 BUT NOT OF SYSTEMIC PROSTACYCLIN BY CONTROLLED-RELEASE ASPIRIN [J].
CLARKE, RJ ;
MAYO, G ;
PRICE, P ;
FITZGERALD, GA .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (16) :1137-1141
[8]  
COLLINS T, 1993, LAB INVEST, V68, P499
[9]   Lipid peroxidation and platelet activation in murine atherosclerosis [J].
Cyrus, T ;
Tang, LX ;
Rokach, J ;
FitzGerald, GA ;
Praticò, D .
CIRCULATION, 2001, 104 (16) :1940-1945
[10]  
FitzGerald GA, 2000, ANN MED, V32, P21